AEROECLIPSE^® II BAN^® Nebulizer Economic Value Calculator

The high efficiency AEROECLIPSE^® II BAN^® Nebulizer has been shown to improve patient outcomes and staff workflow in Emergency Departments. This calculator uses recently published data from JACEP Open to demonstrate the potential cost savings your ED could achieve by implementing it.

Read the Study

Calculator Instructions
Please enter your location’s estimated annual emergency department visits and select a patient condition from the dropdown menu to activate the cost savings calculator. It will automatically populate with values derived from the referenced study. All values are estimated based on the study’s calculations and should be interpreted accordingly. Scroll to the bottom of the page to review your savings and send the complete report to your email.

This calculator uses average values from national datasets (National Hospital Ambulatory Medical Care Survey) and published results from Luo et al. (2025), to estimate clinical and economic outcomes associated with BAN nebulizer implementation. These values are based on population-level averages and do not account for standard deviation, confidence intervals, or institution-specific variability in treatment rates, admission rates, or cost structures. Actual results may differ based on local protocols, patient mix, and real-world implementation. Please refer to the full manuscript for further details.

How many annual Emergency Department visits at your location?(Required)

Enter the total number of annual Emergency Department visits at your location, regardless of the reason for the visit.

Choose a primary patient condition from the dropdown to start your estimate:(Required)

Pediatric Asthma Calculations

This field is hidden when viewing the form

% of Emergency Department visits for pediatric asthma exacerbations:(Required)

2.2% is the average, but you can use your own value if it differs for your hospital. If using your own number, please do not include the % symbol.

Please enter a number from 1 to 100.

Approximate number of pediatric asthma ED visits per year:

This field is hidden when viewing the form

Approximate % of pediatric asthma patients who receive nebulizer treatment:(Required)

On average, 66% of exacerbations receive nebulizer therapy.* That is the default value, but you may input a different figure if needed.

Please enter a number from 1 to 100.

Approximate nebulizer treatments per year for pediatric asthma:

This field is hidden when viewing the form

Average pediatric asthma admission rate with CN:(Required)

7.7% is the average hospital admission rate after receiving nebulizer therapy.*

Please enter a number from 1 to 100.

Approximate number of pediatric asthma admissions per year:

This field is hidden when viewing the form

Average reduction in pediatric asthma patient admissions with BAN:(Required)

33.3% is the average reduction in hospital admissions for pediatric asthma patients after implementation.

Please enter a number from 1 to 100.

Pediatric asthma patient hospital admission reduction with BAN:

Total Number of Reduced Hospital Admissions for Pediatric Patients:

Decreased ED time for pediatric asthma patients per year (hours saved):

This field is hidden when viewing the form

Average reduction in Emergency Department length of stay for pediatric asthma patients:(Required)

The average decrease in ED LOS for pediatric asthma patients is 59 minutes.*

Please enter a number from 1 to 100.

Cost savings in reduced pediatric asthma admissions ($5200 average):

Decrease Emergency Department length of stay costs:

Added cost of the BAN Nebulizer over SJN:

Estimated Cost Savings For Pediatric Asthma (in $):

Total estimated cost savings for pediatric asthma:

Adult Asthma Calculations

This field is hidden when viewing the form

% of Emergency Department visits for adult asthma exacerbations:(Required)

0.86% is the average, but you can use your own value if it differs for your hospital. If using your own number, please do not include the % symbol.

Please enter a number from 1 to 100.

Approximate number of adult asthma ED visits per year:

This field is hidden when viewing the form

% of adult asthma patients who receive nebulizer treatment (57% = average):(Required)

Please enter a number from 1 to 100.

Approximate number of nebulizer treatments per year for adult asthma:

This field is hidden when viewing the form

Current adult asthma admission rate with CN(Required)

Please enter a number from 1 to 100.

Approximate number of adult asthma patient admissions after nebulizer treatment:

This field is hidden when viewing the form

Adult Asthma Admission Rate with BAN (72% = average):(Required)

Please enter a number from 1 to 100.

Average reduction in adult asthma patient admissions with BAN:

Total number of reduced hospital admissions for adult asthma patients:

Increase in Emergency Department time for adult asthma patients per year (minutes):

This field is hidden when viewing the form

Adult Asthma Length of Stay Increase (13.1 minutes = average):(Required)

Please enter a number from 1 to 100.

Total cost savings in reduced hospital admissions for adult asthma patients using the BAN Nebulizer:

Added cost of the BAN Nebulizer over SJN for adult asthma patients:

Added cost of increased length of stay (LOS):

Estimated Cost Savings For Adult Asthma (in $):

Total estimated cost savings for adult asthma:

COPD Calculations

This field is hidden when viewing the form

% of emergency visits for COPD (0.94% = average):(Required)

Please enter a number from 1 to 100.

Approximate number of COPD visits to the Emergency Department per year:

This field is hidden when viewing the form

% of COPD patients who receive nebulizer treatment (41% = average):(Required)

Please enter a number from 1 to 100.

Approximate number of nebulizer treatments per year for COPD:

This field is hidden when viewing the form

Current COPD Admission Rate with CN (41.2% = average):(Required)

Please enter a number from 1 to 100.

Approximate number of hospital admissions for COPD patients with CN:

This field is hidden when viewing the form

COPD Admission Rate with BAN (45.6% = average):(Required)

Please enter a number from 1 to 100.

Approximate number of hospital admissions for COPD patients with BAN:

Reduction in COPD patient admissions with the AEROECLIPSE® II BAN® Nebulizer:

This field is hidden when viewing the form

COPD Admission Cost ($6,852 = average):(Required)

Cost savings in reduced hospital admissions for COPD patients using the BAN Nebulizer (average $6852):

Added cost of the BAN Nebulizer over SJN for COPD patients:

Estimated Cost Savings For COPD (in $):

Total estimated cost savings for COPD:

Additional Cost Savings for Pediatric Asthma:

This field is hidden when viewing the form

% of Emergency Department visits for pediatric asthma exacerbations:(Required)

2.2% is the average, but you can use your own value if it differs for your hospital. If using your own number, please do not include the % symbol.

Please enter a number from 1 to 100.

Approximate number of pediatric asthma ED visits per year:

This field is hidden when viewing the form

Approximate % of pediatric asthma patients who receive nebulizer treatment:(Required)

On average, 66% of exacerbations receive nebulizer therapy.* That is the default value, but you may input a different figure if needed.

Please enter a number from 1 to 100.

Approximate nebulizer treatments per year for pediatric asthma:

This field is hidden when viewing the form

Average pediatric asthma admission rate with CN:(Required)

7.7% is the average hospital admission rate after receiving nebulizer therapy.*

Please enter a number from 1 to 100.

Approximate number of pediatric asthma admissions per year:

This field is hidden when viewing the form

Average reduction in pediatric asthma patient admissions with BAN:(Required)

33.3% is the average reduction in hospital admissions for pediatric asthma patients after implementation.

Please enter a number from 1 to 100.

Pediatric asthma patient hospital admission reduction with BAN:

Total Number of Reduced Hospital Admissions for Pediatric Patients:

This field is hidden when viewing the form

Average reduction in Emergency Department length of stay for pediatric asthma patients:(Required)

The average decrease in ED LOS for pediatric asthma patients is 59 minutes.*

Please enter a number from 1 to 100.

Decreased Emergency Department time for pediatric asthma patients per year (hours saved):

Cost savings in reduced pediatric asthma admissions ($5200 average):

Decrease Emergency Department length of stay costs:

Added cost of the BAN Nebulizer over SJN:

Estimated Cost Savings For Pediatric Asthma (in $):

Total estimated cost savings for pediatric asthma:

Additional Cost Savings for Adult Asthma:

This field is hidden when viewing the form

% of Emergency Department visits for adult asthma exacerbations:(Required)

0.86% is the average, but you can use your own value if it differs for your hospital. If using your own number, please do not include the % symbol.

Please enter a number from 1 to 100.

Approximate number of adult asthma ED visits per year:

This field is hidden when viewing the form

% of adult asthma patients who receive nebulizer treatment (57% = average):(Required)

Please enter a number from 1 to 100.

Approximate number of nebulizer treatments per year for adult asthma:

This field is hidden when viewing the form

Current adult asthma admission rate with CN(Required)

Please enter a number from 1 to 100.

Approximate number of adult asthma patient admissions after nebulizer treatment:

This field is hidden when viewing the form

Adult Asthma Admission Rate with BAN (72% = average):(Required)

Please enter a number from 1 to 100.

Average reduction in adult asthma patient admissions with BAN:

Total number of reduced hospital admissions for adult asthma patients:

This field is hidden when viewing the form

Adult Asthma Length of Stay Increase (13.1 minutes = average):(Required)

Please enter a number from 1 to 100.

Increase in Emergency Department time for adult asthma patients per year (minutes):

This field is hidden when viewing the form

Adult Asthma Admission Cost ($6,688 = average):(Required)

Total cost savings in reduced hospital admissions for adult asthma patients using the BAN Nebulizer:

Added cost of the BAN Nebulizer over SJN for adult asthma patients:

Added cost of increased length of stay (LOS):

Estimated Cost Savings For Adult Asthma (in $):

Total estimated cost savings for adult asthma:

Additional Cost Savings for COPD:

This field is hidden when viewing the form

% of emergency visits for COPD (0.94% = average):(Required)

Please enter a number from 1 to 100.

Approximate number of COPD visits to the Emergency Department per year:

This field is hidden when viewing the form

% of COPD patients who receive nebulizer treatment (41% = average):(Required)

Please enter a number from 1 to 100.

Approximate number of nebulizer treatments per year for COPD:

This field is hidden when viewing the form

Current COPD Admission Rate with CN (41.2% = average):(Required)

Please enter a number from 1 to 100.

Approximate number of hospital admissions for COPD patients with CN:

This field is hidden when viewing the form

COPD Admission Rate with BAN (45.6% = average):(Required)

Please enter a number from 1 to 100.

Approximate number of hospital admissions for COPD patients with BAN:

Reduction in COPD patient admissions with the AeroEclipse II BAN Nebulizer:

This field is hidden when viewing the form

COPD Admission Cost ($6,852 = average):(Required)

Cost savings in reduced hospital admissions for COPD patients (average $6852):

Added cost of the BAN Nebulizer over SJN for COPD patients:

Estimated Cost Savings For COPD (in $):

Total estimated cost savings for COPD:

Net Total

Total Estimated Cost Savings For Your Emergency Department (in $):

This is the sum of estimated cost savings figures for all three patient conditions.

Total Estimated Cost Savings For Your Emergency Department (in $):(Required)

Would you like an emailed copy of these findings with a full breakdown of the calculations?(Required)

To receive the full report, please enter your contact information below:

What is Your Name?(Required)

What is Your Email Address?(Required)

What is Your Hospital/Facility Name?(Required)

Name

This field is for validation purposes and should be left unchanged.

Breath-Actuated Nebulizers for Asthma and Chronic Obstructive Pulmonary Disease Exacerbation: A Monte Carlo Simulation Demonstrating National Cost Savings and Length of Stay Reduction

^*Andrew D. Luo, DaMarcus E. Baymon, Gregory A. Peters, Joshua M. Kosowsky, Lauren M. Nentwich, Joshua J. Baugh, Christopher W. Baugh. JACEP Open, Volume 6, Issue 3, 100112

Abstract

Objectives: Breath-actuated nebulizers (BANs) deliver medication only during inspiration, and prior studies have demonstrated their increased efficacy for asthma and chronic obstructive pulmonary disease (COPD) exacerbations compared to continuous nebulizers. However, the widespread adoption of BAN has been limited by its higher per-unit cost. Our primary objective was to estimate the annual national net cost and emergency department (ED) bed-hour savings of switching to BAN for pediatric and adult patients presenting to the ED with asthma or COPD exacerbation.

Methods: We estimated the prevalence of ED visits for asthma and COPD requiring nebulizer treatment using publicly available datasets. We created a Monte Carlo model and ran 1000 trials to determine the marginal cost of a BAN-first approach. We modeled the cost savings from decreased ED bed hours and averted inpatient admissions among eligible patients nationally and by common annual ED visit volumes.

Results: Adoption of a BAN-first strategy nationally is estimated to incur an additional $6,059,000 (±$1,024,000) in supply costs, with total savings of $744,610,000 (±$141,922,000) and a reduction of 178,000 (±77,000) ED bed hours. An ED with 30,000 annual visits would save $206,000 (±$38,000) annually with a supply cost of $1400 (±$260). For 60,000 visits, savings would be $551,000 (±$99,600) with a supply cost of $3700 (±$680). At 130,000 visits, savings would reach $896,000 (±$168,000) with a supply cost of $5900 (±$1100).

Conclusion: BAN may yield significant cost savings driven primarily by a decreased likelihood of admission for COPD exacerbation. Further research is needed to validate clinical efficacy and address barriers to adoption.

Keywords: asthma exacerbation, COPD exacerbation, nebulizer, breath-actuated, cost savings, Monte Carlo simulation, length of stay reduction

AEROECLIPSE® II BAN® Nebulizer Economic Value Calculator

AEROECLIPSE® II BAN® Nebulizer Economic Value Calculator

Pediatric Asthma Calculations

Estimated Cost Savings For Pediatric Asthma (in $):

Adult Asthma Calculations

Estimated Cost Savings For Adult Asthma (in $):

COPD Calculations

Estimated Cost Savings For COPD (in $):

Additional Cost Savings for Pediatric Asthma:

Estimated Cost Savings For Pediatric Asthma (in $):

Additional Cost Savings for Adult Asthma:

Estimated Cost Savings For Adult Asthma (in $):

Additional Cost Savings for COPD:

Estimated Cost Savings For COPD (in $):

Net Total

Total Estimated Cost Savings For Your Emergency Department (in $):

To receive the full report, please enter your contact information below:

Breath-Actuated Nebulizers for Asthma and Chronic Obstructive Pulmonary Disease Exacerbation: A Monte Carlo Simulation Demonstrating National Cost Savings and Length of Stay Reduction

Abstract

AEROECLIPSE^® II BAN^® Nebulizer Economic Value Calculator

AEROECLIPSE^® II BAN^® Nebulizer Economic Value Calculator